165 related articles for article (PubMed ID: 34400619)
1. How the glucocorticoid receptor contributes to platinum-based therapy resistance in solid cancer.
Clarisse D; De Bosscher K
Nat Commun; 2021 Aug; 12(1):4959. PubMed ID: 34400619
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin-mediated activation of glucocorticoid receptor induces platinum resistance via MAST1.
Pan C; Kang J; Hwang JS; Li J; Boese AC; Wang X; Yang L; Boggon TJ; Chen GZ; Saba NF; Shin DM; Magliocca KR; Jin L; Kang S
Nat Commun; 2021 Aug; 12(1):4960. PubMed ID: 34400618
[TBL] [Abstract][Full Text] [Related]
3. The Role of mTORC1 Pathway and Autophagy in Resistance to Platinum-Based Chemotherapeutics.
Pan Z; Zhang H; Dokudovskaya S
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445831
[TBL] [Abstract][Full Text] [Related]
4. Delivery of platinum (II) drugs with bulky ligands in trans-geometry for overcoming cisplatin drug resistance.
Yang X; Yu Y; Huang X; Chen Q; Wu H; Wang R; Qi R; Miao Y; Qiu Y
Mater Sci Eng C Mater Biol Appl; 2019 Mar; 96():96-104. PubMed ID: 30606608
[TBL] [Abstract][Full Text] [Related]
5. Contributions of the Epidermal Growth Factor Receptor to Acquisition of Platinum Resistance in Ovarian Cancer Cells.
Granados ML; Hudson LG; Samudio-Ruiz SL
PLoS One; 2015; 10(9):e0136893. PubMed ID: 26351843
[TBL] [Abstract][Full Text] [Related]
6. Estrogen- and estrogen receptor (ER)-mediated cisplatin chemoresistance in cancer.
Berkel C; Cacan E
Life Sci; 2021 Dec; 286():120029. PubMed ID: 34634322
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy.
Makovec T
Radiol Oncol; 2019 Mar; 53(2):148-158. PubMed ID: 30956230
[TBL] [Abstract][Full Text] [Related]
8. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer.
Isikbay M; Otto K; Kregel S; Kach J; Cai Y; Vander Griend DJ; Conzen SD; Szmulewitz RZ
Horm Cancer; 2014 Apr; 5(2):72-89. PubMed ID: 24615402
[TBL] [Abstract][Full Text] [Related]
9. High level resistance to glucocorticoids, associated with a dysfunctional glucocorticoid receptor, in childhood acute lymphoblastic leukemia cells selected for methotrexate resistance.
Catts VS; Farnsworth ML; Haber M; Norris MD; Lutze-Mann LH; Lock RB
Leukemia; 2001 Jun; 15(6):929-35. PubMed ID: 11417479
[TBL] [Abstract][Full Text] [Related]
10. Expression of the glucocorticoid receptor and its isoforms in relation to glucocorticoid resistance in childhood acute lymphocytic leukemia.
Tissing WJ; Lauten M; Meijerink JP; den Boer ML; Koper JW; Sonneveld P; Pieters R
Haematologica; 2005 Sep; 90(9):1279-81. PubMed ID: 16154856
[TBL] [Abstract][Full Text] [Related]
11. ATP11B mediates platinum resistance in ovarian cancer.
Moreno-Smith M; Halder JB; Meltzer PS; Gonda TA; Mangala LS; Rupaimoole R; Lu C; Nagaraja AS; Gharpure KM; Kang Y; Rodriguez-Aguayo C; Vivas-Mejia PE; Zand B; Schmandt R; Wang H; Langley RR; Jennings NB; Ivan C; Coffin JE; Armaiz GN; Bottsford-Miller J; Kim SB; Halleck MS; Hendrix MJ; Bornman W; Bar-Eli M; Lee JS; Siddik ZH; Lopez-Berestein G; Sood AK
J Clin Invest; 2013 May; 123(5):2119-30. PubMed ID: 23585472
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin: The first metal based anticancer drug.
Ghosh S
Bioorg Chem; 2019 Jul; 88():102925. PubMed ID: 31003078
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review.
Stordal B; Pavlakis N; Davey R
Cancer Treat Rev; 2007 Jun; 33(4):347-57. PubMed ID: 17383100
[TBL] [Abstract][Full Text] [Related]
14. DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN-WEE1 Signaling.
Li J; Pan C; Boese AC; Kang J; Umano AD; Magliocca KR; Yang W; Zhang Y; Lonial S; Jin L; Kang S
Clin Cancer Res; 2020 Jul; 26(14):3843-3855. PubMed ID: 32341033
[TBL] [Abstract][Full Text] [Related]
15. Glucocorticoid receptor alpha, beta and gamma expression vs in vitro glucocorticod resistance in childhood leukemia.
Haarman EG; Kaspers GJ; Pieters R; Rottier MM; Veerman AJ
Leukemia; 2004 Mar; 18(3):530-7. PubMed ID: 14724649
[TBL] [Abstract][Full Text] [Related]
16. New-generation platinum drugs in the treatment of cisplatin-resistant cancers.
McKeage MJ
Expert Opin Investig Drugs; 2005 Aug; 14(8):1033-46. PubMed ID: 16050795
[TBL] [Abstract][Full Text] [Related]
17. Duality of glucocorticoid action in cancer: tumor-suppressor or oncogene?
Mayayo-Peralta I; Zwart W; Prekovic S
Endocr Relat Cancer; 2021 May; 28(6):R157-R171. PubMed ID: 33852423
[TBL] [Abstract][Full Text] [Related]
18. Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment.
Wang Z; Deng Z; Zhu G
Dalton Trans; 2019 Feb; 48(8):2536-2544. PubMed ID: 30633263
[TBL] [Abstract][Full Text] [Related]
19. Receptor mutation is not a common mechanism of naturally occurring glucocorticoid resistance in leukaemia cell lines.
Beesley AH; Weller RE; Senanayake S; Welch M; Kees UR
Leuk Res; 2009 Feb; 33(2):321-5. PubMed ID: 18789525
[TBL] [Abstract][Full Text] [Related]
20. Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease.
Egan JB; Kortuem KM; Kurdoglu A; Izatt T; Aldrich J; Reiman R; Phillips L; Baker A; Shi CX; Schmidt J; Liang WS; Craig DW; Carpten JD; Stewart AK
Br J Haematol; 2013 Jun; 161(5):748-751. PubMed ID: 23480694
[No Abstract] [Full Text] [Related]
[Next] [New Search]
